{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:18:49Z","timestamp":1790291929709,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40263-021-00893-y","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T03:02:31Z","timestamp":1644548551000},"page":"191-202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score"],"prefix":"10.1007","volume":"36","author":[{"given":"Luigi Francesco","family":"Iannone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Fattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Benemei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Chiarugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangelo","family":"Geppetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cesaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"issue":"383","key":"893_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"2020","author":"M Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;2020(383):1866\u201376.","journal-title":"N Engl J Med"},{"issue":"21","key":"893_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"2020","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, et al. European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;2020(21):76.","journal-title":"J Headache Pain"},{"issue":"5","key":"893_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098614522683","volume":"2014","author":"ES Kristoffersen","year":"2014","unstructured":"Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014;2014(5):87\u201399.","journal-title":"Ther Adv Drug Saf."},{"issue":"20","key":"893_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"2019","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;2019(20):6.","journal-title":"J Headache Pain"},{"key":"893_CR5","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3390\/ph14070700","volume":"14","author":"T Mavridis","year":"2021","unstructured":"Mavridis T, Deligianni CI, Karagiorgis G, Daponte A, Breza M, Mitsikostas DD. Monoclonal antibodies targeting CGRP: from clinical studies to real-world evidence\u2014what do we know so far? Pharmaceuticals. 2021;14:2021.","journal-title":"Pharmaceuticals"},{"issue":"28","key":"893_CR6","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"2021","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, et al. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;2021(28):1716\u201325.","journal-title":"Eur J Neurol"},{"issue":"60","key":"893_CR7","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1111\/head.13918","volume":"2020","author":"S Cape","year":"2020","unstructured":"Cape S. Access to migraine treatments in Ontario, Canada: a review of the ontario drug benefit program. Headache. 2020;2020(60):1888\u2013900.","journal-title":"Headache"},{"issue":"21","key":"893_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"2020","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;2020(21):61.","journal-title":"J Headache Pain"},{"key":"893_CR9","doi-asserted-by":"crossref","unstructured":"Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol. 2021.","DOI":"10.1007\/s00415-021-10523-8"},{"key":"893_CR10","unstructured":"Attivazione web e pubblicazione schede di monitoraggio - Registro AIMOVIG. URL https:\/\/www.aifa.gov.it\/en\/-\/attivazione-web-e-pubblicazione-schede-di-monitoraggio-registro-aimovig (assessed 8 december 2021)"},{"issue":"21","key":"893_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"2020","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M,Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020;2020(21):69.","journal-title":"J Headache Pain"},{"issue":"60","key":"893_CR12","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"2020","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache. 2020;2020(60):2014\u201325.","journal-title":"Headache"},{"issue":"11","key":"893_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","volume":"2020","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, Reuter U. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxina: a dual-center retrospective observational study. Front Neurol. 2020;2020(11):417.","journal-title":"Front Neurol"},{"issue":"21","key":"893_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"2020","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;2020(21):32.","journal-title":"J Headache Pain"},{"issue":"61","key":"893_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"2021","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, et al. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021;2021(61):363\u201372.","journal-title":"Headache"},{"issue":"41","key":"893_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10072-020-04669-y","volume":"2020","author":"F Vernieri","year":"2020","unstructured":"Vernieri F, Altamura C, Aurilia C, Brunelli N, Egeo G, Fofi L, et al. Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). Neurol Sci. 2020;2020(41):487\u20138.","journal-title":"Neurol Sci"},{"key":"893_CR17","doi-asserted-by":"crossref","unstructured":"Schiano di Cola F, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U, et al. Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study. Neurol Sci 2020;41:489\u201390.","DOI":"10.1007\/s10072-020-04670-5"},{"issue":"21","key":"893_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"2020","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, et al. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence. J Headache Pain. 2020;2020(21):84.","journal-title":"J Headache Pain"},{"issue":"41","key":"893_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10072-020-04667-0","volume":"2020","author":"E Matteo","year":"2020","unstructured":"Matteo E, Favoni V, Pascazio A, Pensato U, Benini M, Asioli GM, et al. Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center. Neurol Sci. 2020;2020(41):483\u20134.","journal-title":"Neurol Sci"},{"issue":"40","key":"893_CR20","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"2020","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia. 2020;2020(40):1511\u201322.","journal-title":"Cephalalgia"},{"issue":"60","key":"893_CR21","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"2020","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E. Erenumab in chronic migraine: an Australian experience. Headache. 2020;2020(60):2555\u201362.","journal-title":"Headache"},{"issue":"22","key":"893_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"2021","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, et al. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;2021(22):35.","journal-title":"J Headache Pain"},{"issue":"41","key":"893_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10072-020-04677-y","volume":"2020","author":"A Ranieri","year":"2020","unstructured":"Ranieri A, Alfieri G, Napolitano M, Servillo G, Candelaresi P, Di Iorio W, et al. One year experience with erenumab: real-life data in 30 consecutive patients. Neurol Sci. 2020;2020(41):505\u20136.","journal-title":"Neurol Sci"},{"key":"893_CR24","doi-asserted-by":"crossref","unstructured":"Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, et al. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache. 2021(2021).","DOI":"10.1111\/head.14194"},{"issue":"40","key":"893_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"2020","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein SD, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. Cephalalgia. 2020;2020(40):543\u201353.","journal-title":"Cephalalgia"},{"key":"893_CR26","unstructured":"Detke H, Pozo-Rosich P, Reuter U, Dolezil D, Li L, Wang S, Aurora S. One-year treatment with galcanezumab in patients with chronic migraine: results from the open-label phase of the REGAIN study (P2.10-010). Neurology. 2019;92:2019."},{"issue":"16 Suppl 1","key":"893_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00023210-200216001-00004","volume":"2002","author":"D Dodick","year":"2002","unstructured":"Dodick D. Patient perceptions and treatment preferences in migraine management. CNS Drugs. 2002;2002(16 Suppl 1):19\u201324.","journal-title":"CNS Drugs"},{"issue":"88","key":"893_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0304-3959(00)00305-5","volume":"2000","author":"WF Stewart","year":"2000","unstructured":"Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;2000(88):41\u201352.","journal-title":"Pain"},{"key":"893_CR29","doi-asserted-by":"crossref","unstructured":"Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, et al. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci. 2021(2021).","DOI":"10.1007\/s10072-021-05426-5"},{"issue":"16","key":"893_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"2017","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;2017(16):425\u201334.","journal-title":"Lancet Neurol"},{"issue":"60","key":"893_CR31","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/head.13849","volume":"2020","author":"R Burstein","year":"2020","unstructured":"Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of action of onabotulinumtoxina in chronic migraine: a narrative review. Headache. 2020;2020(60):1259\u201372.","journal-title":"Headache"},{"key":"893_CR32","doi-asserted-by":"crossref","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. Pain Ther. 2021(2021).","DOI":"10.1007\/s40122-021-00264-x"},{"issue":"92","key":"893_CR33","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"2019","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019;2019(92):e2309\u201320.","journal-title":"Neurology"},{"issue":"22","key":"893_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10194-021-01238-2","volume":"2021","author":"SJ Tepper","year":"2021","unstructured":"Tepper SJ, Fang J, Vo P, Shen Y, Zhou L, Abdrabboh A, et al. Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study. J Headache Pain. 2021;2021(22):27.","journal-title":"J Headache Pain"},{"key":"893_CR35","doi-asserted-by":"crossref","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A. Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand. 2021(2021).","DOI":"10.1111\/ane.13472"},{"issue":"18","key":"893_CR36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","volume":"2017","author":"M Deen","year":"2017","unstructured":"Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E, et al. Blocking CGRP in migraine patients\u2014a review of pros and cons. J Headache Pain. 2017;2017(18):96.","journal-title":"J Headache Pain"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00893-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00893-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00893-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T14:21:52Z","timestamp":1645539712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00893-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["893"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00893-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"22 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Firenze within the CRUI-CARE Agreement. This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PG received personal fees from Allergan, Eli Lilly, Novartis, Amgen, and TEVA and grants from Amgen, TEVA, Eli-Lilly, Allergan, and Chiesi; was involved in the Scientific Advisory Board, Endosome Therapeutics; and is the founding scientist of FloNext srl, Spinoff of the University of Florence. FDC received personal fees from TEVA, Eli Lilly, and Novartis. LFI, DF, SB, and AC declare no conflicting interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data collected and analyzed for the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The study was approved as a part of the <i>Registro Italiano Cefalee<\/i> (RICe) study by the local Ethics committee (Studio RICe, 14591_oss).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained from every patient.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"PG, LFI, and FDC designed the study; LFI, DF, SB, AC, FDC, and PG performed the research; and LFI, PG, and FDC analyzed and interpreted the data. PG, DF, SB, AC, and FDC critically revised the draft manuscript. All authors critically reviewed the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}